Calidi Biotherapeutics Inc. (CLDI)
NYSE: CLDIHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CLDI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.82M
- EPS (TTM)
- -$36.47
- Dividend yield
- None
- 52-week range
- 0.986 – 27.84
- Day range
- 1.00 – 1.04
- Volume / Avg
- 18.25K / 255.53K
- Beta
- —
- Shares outstanding
- 3.68M
52-week range
CLDI stock today
Calidi Biotherapeutics (CLDI) closed at $1.04 on Oct 8, up 2.97% (+$0.03), versus the S&P 500's 0.47% decline. Trading was light, with 18.25K shares changing hands, about 7% of the average daily volume. At this level, CLDI sits near the bottom of its 52-week range of $0.986 to $27.84: 96.3% below the high and 5.5% above the low.
Calidi Biotherapeutics has posted a net loss over the last twelve months (EPS of -$36.47), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Calidi Biotherapeutics
Company profileCalidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Eric E. Poma Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 29
- IPO year
- 2021
- Website
- calidibio.com
Calidi Biotherapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EOCNEocene Ltd. | 3.62 | +4.69% | $3.87M | vs CLDI |
| PCSAProcessa Pharmaceuticals Inc. | 1.35 | -4.93% | $3.77M | vs CLDI |
| GRIGRI Bio Inc. | 1.68 | -9.19% | $3.67M | vs CLDI |
| JUNSJupiter Neurosciences Inc. | 2.77 | -2.46% | $3.65M | vs CLDI |
| ERNAErnexa Therapeutics Inc. | 2.49 | +4.18% | $4.06M | vs CLDI |
| ONCOOnconetix Inc. | 0.6543 | +9.56% | $3.43M | vs CLDI |
| HCWBHCW Biologics Inc. | 1.53 | -1.92% | $3.42M | vs CLDI |
| SXTP60 Degrees Pharmaceuticals Inc. | 0.9725 | -11.59% | $3.42M | vs CLDI |
Indexes, lists and sector
Appears in lists
Calidi Biotherapeutics stock FAQ
What is Calidi Biotherapeutics's stock price today?
CLDI last traded at $1.04 as of Oct 8, 4:00 PM EDT, up 2.97% on the day. Prices are delayed at least 15 minutes.
Who is Calidi Biotherapeutics's CEO?
Dr. Eric E. Poma Ph.D. is the chief executive officer of Calidi Biotherapeutics Inc., which has about 29 employees.
What is the CLDI 52-week high?
The 52-week high for CLDI is $27.84 and the 52-week low is $0.986. The stock is currently 96.3% below its high.